Barrett Esophagus, Dysplasia in Barrett Esophagus, Esophageal Cancer
Conditions
Keywords
BE, EAC, HGD, Esophagus
Brief summary
To improve detection of esophageal (pre)malignant lesions during surveillance endoscopy of patients at risk of developing malignancies, for example in Barrett's Esophagus (BE), there is a need for better endoscopic visualization and the ability for targeted biopsies. Optical molecular imaging of neoplasia associated biomarkers could form a promising technique to accommodate this need. It is known that the biomarker c-Met is overexpressed in dysplastic and neoplastic areas in BE segments versus normal tissue and has proven to be a valid target for molecular imaging. Edinburgh Molecular Imaging Ltd (EMI) has developed a fluorescent tracer specifically targeting c-Met by labeling a small peptide to a fluorescent fluorophore: 'EMI-137'. The investigators hypothesize that when EMI-137 is administered intravenously, it accumulates in c-Met expressing high grade dysplasia (HGD) and esophageal adenocarcinoma (EAC), enabling (early) cancer visualization using a newly developed fluorescent fiber-bundle. This hypothesis will be tested in the current pilot intervention study.
Detailed description
See brief summary.
Interventions
DRUGIV-administation of EMI-137
Intravenous administration of 0.13 mg/kg of the fluorescent tracer EMI-137 approximately 2.5 hours prior to the endoscopy procedure.
A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe is inserted through the standard working-channel of the standard clinical endoscope. Fluorescence imaging will be performed prior to and post the endoscopic resection, during the same endoscopy procedure.
Sponsors
University Medical Center Groningen
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 years, eligible for a diagnostic and/or therapeutic endoscopy; * At least a suspicion of low grade dysplasia (LGD) based on a prior endoscopy; * World Health Organization (WHO) performance score of 0-2; * Written informed consent; * Mentally competent person that is able and willing to comply with study procedures; * For female subjects who are of childbearing potential, are premenopausal with intact reproductive organs or are less than 2 years post-menopausal: * A negative serum pregnancy test prior to receiving the tracer; * Willing to ensure that she or her partner uses effective contraception during the trial and for 3 months thereafter.
Exclusion criteria
* Pregnancy or breast feeding; * Advanced stage EAC patient not suitable for endoscopic resection; * Medical or psychiatric conditions that compromise the patient's ability to give informed consent; * Concurrent anticancer therapy (chemotherapy, radiotherapy, vaccines, immunotherapy) delivered within the last three months prior to the start of the treatment * The subject has been included previously in this study or has been injected with another investigational medicinal product within the past six months. * History of myocardial infarction (MI), Transient Ischemic Attack (TIA), CerebroVascular Accident (CVA), pulmonary embolism, uncontrolled congestive heart failure (CHF), significant liver disease, unstable angina within 6 months prior to enrollment. * The subject had any significant change in their regular prescription or non-prescription medication between 14 days and 1 day prior to Investigational Medicinal Product (IMP) administration. Occasional use of analgesics, such as non-steroid anti-inflammatory drugs and/or paracetamol, was permitted at the discretion of the investigator. Use of hormonal contraceptives is permitted.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Tumor-to-background ratio that allows the in vivo detection of (pre)malignant lesions in patients with Barrett's Esophagus using molecular fluorescence endoscopy. | Day 1 | Calculation of the in vivo tumor-to-background ratio (\> 1.5) based on fluorescence intensities in (pre)malignant lesions compared to surrounding healthy esophageal tissue. |
| Safety: the number of participants with symptoms or changes in vital signs (blood pressure, heart frequency and temperature) and/or (serious) adverse events that are related to administration of EMI-137. | Up to day 3 | — |
Secondary
| Measure | Time frame |
|---|---|
| The correlation of fluorescence signals to histopathology from (pre)malignant lesions and surrounding normal esophageal tissue. | Up to 1 year |
| Identification of fluorescence lesions and correlation with histopathology on subsequent biopsies in the resection surface after endoscopic mucosal resection. | Up to 1 year |
| Quantification of fluorescence signals in vivo and ex vivo of (pre)malignant lesions and normal esophageal tissue using multi-diameter single-fiber reflectance single-fiber fluorescence (MDSFR-SFF) spectroscopy. | Up to 1 year |
| Visualization of the localization and distribution patterns of EMI-137 in the esophagus using ex vivo fluorescence microscopy. | Up to 1 year |
Countries
Netherlands
Outcome results
None listed